Evidence map›Paper›PMID 36923274›Full record

ArticleFrontiers in pediatrics2023

Analysis of the impact of the SARS-CoV-2 infection on the pediatric population hospitalized during the pandemic in the Greater Paris University Hospitals.

Michaela Semeraro, Pierre Pinson, Margaux Populaire, Mourad Dellagi, Mehdi Oualha, Nathanael Beeker, Hélène Chappuy

Open access · goldFull text read
In one paragraph

Article in Frontiers in pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Michaela SemeraroCentre D'Investigation Clinique-Unité de Recherche Clinique, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.
Pierre PinsonEA7323 Pediatric and Perinatal Drug Evaluation and Pharmacology, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Margaux PopulaireCentre D'Investigation Clinique-Unité de Recherche Clinique, Hôpital Universitaire Necker Enfants-Malades, GH Paris Centre, Paris, France.
Mourad DellagiEA7323 Pediatric and Perinatal Drug Evaluation and Pharmacology, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Mehdi OualhaEA7323 Pediatric and Perinatal Drug Evaluation and Pharmacology, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Nathanael BeekerEA7323 Pediatric and Perinatal Drug Evaluation and Pharmacology, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Hélène ChappuyEA7323 Pediatric and Perinatal Drug Evaluation and Pharmacology, Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Université Paris Cité · FRHôpital Necker-Enfants Malades · FRAssistance Publique – Hôpitaux de Paris · FRHôpital Cochin · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The clinical characteristics, disease progression and outcome in children affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection appear significantly milder compared to older individuals. Nevertheless, the trends in hospitalization and clinical characteristics in the pediatric population seem to be different over time across the different epidemic waves. Objective: Our aim was to understand the impact of the different COVID-19 variants in the pediatric population hospitalized in the Pediatric Departments of the Public Hospital in the Greater Paris area by the analysis performed with the Assistance Publique-Hopitaux de Paris (AP-HP) Health Data Warehouse. Methods: This is a retrospective cohort study including 9,163 patients under 18 years of age, hospitalized from 1 March 2020 to 22 March 2022, in the Paris area, with confirmed infection by SARS-CoV-2. Three mutually exclusive groups with decreasing severity (Pediatric Inflammatory Multisystem Syndrome (PIMS), symptomatic infection, mild or asymptomatic infection) were defined and described regarding demography, medical history, complication of the SARS-CoV-2 infection, and treatment during admission. Temporal evolution was described by defining three successive waves (March-September 2020, October 2020-October 2021, and November 2021-March 2022) corresponding to the emergence of the successive variants. Results: In the study period, 9,163 pediatric patients with SARS-CoV-2 infection were hospitalized in 21 AP-HP hospitals. The number of patients with SARS-CoV-2 infection increased over time for each wave of the pandemic (the mean number of patients per month during the first wave was 332, 322 during the 2nd, and 595 during the third wave). In the medical history, the most associated concomitant disease was chronic respiratory disease. Patients hospitalized during the third wave presented a higher incidence of pulmonary involvement (10.2% compared to 7% and 6.5% during the first and second waves, respectively). The highest incidence of PIMS was observed during the first and second waves (4.2% in the first and second waves compared to 2.3% in the 3rd wave). Discussion: This analysis highlighted the high incidence of hospitalized children in the Greater Paris Area during the third wave of SARS-CoV-2 pandemic corresponding to the Omicron Covid-19 variant, which is probably an expression of a concomitant SARS-CoV-2, while a decreased incidence of PIMS complication was observed during the same period.

Indexed as

childrendata warehousehospitalized childMIS-C multisystem inflammatory syndrome in childrenPIMSSARS-CoV-2

Identifiers

PMID36923274
PMCPMC10009109
OpenAlexW4322503036

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read223
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.